Tong Liu1,2,3, Qingsong Zhang4, Yiming Wang5, Liying Cao6, Hanping Shi7,8,9, Xiangming Ma5, Qi Zhang1,2,3, Mengmeng Song1,2,3. 1. Department of Gastrointestinal Surgery/Clinical Nutrition, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China. 2. Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing, 100038, China. 3. Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, China. 4. Department of General Surgery, Kailuan General Hospital, Tangshan, China. 5. Department of Hepatological Surgery, Kailuan General Hospital, Tangshan, 063000, China. 6. Department of Hepatological Surgery, Kailuan General Hospital, Tangshan, 063000, China. lyc176700@mail.ccmu.edu.cn. 7. Department of Gastrointestinal Surgery/Clinical Nutrition, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China. shihp@ccmu.edu.cn. 8. Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing, 100038, China. shihp@ccmu.edu.cn. 9. Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, China. shihp@ccmu.edu.cn.
Abstract
BACKGROUND: No previous prospective research has explored the association of the TyG (fasting triglyceride-glucose) index and TG/HDL-C ratio as insulin resistance markers with the risk of colorectal cancer (CRC) incidence in the Northern Chinese population. METHODS: In this prospective cohort study, we included 93,659 cancer-free participants with the measurements of TyG index and TG/HDL-C ratio. Participants were divided by the quartiles of the TyG index or TG/HDL-C ratio. The associations of TyG index, TG/HDL-C ratio, and their components with CRC risk were assessed using Cox proportional hazards regression models. RESULTS: During a median follow-up of 13.02 years, 593 incident CRC cases were identified. Compared with the lowest quartile of the TyG index (Q1), the risk of CRC was higher in persons in the third (Q3) and highest quartiles (Q4) of the TyG index, with corresponding multivariable-adjusted HRs (95% CI) of 1.36 (1.06, 1.76) and 1.50 (1.19, 1.91), respectively. The elevated risks of CRC incidence were observed in people in the second, third, and highest quartiles of the TG/HDL-C ratio groups, with corresponding multivariable-adjusted HRs (95% CI) of 1.33 (1.05, 1.70), 1.36 (1.07, 1.73) and 1.37 (1.07, 1.75), respectively. CONCLUSIONS: Elevated TyG index and TG/HDL-C ratio were associated with a higher risk of developing CRC among adults in Northern China.
BACKGROUND: No previous prospective research has explored the association of the TyG (fasting triglyceride-glucose) index and TG/HDL-C ratio as insulin resistance markers with the risk of colorectal cancer (CRC) incidence in the Northern Chinese population. METHODS: In this prospective cohort study, we included 93,659 cancer-free participants with the measurements of TyG index and TG/HDL-C ratio. Participants were divided by the quartiles of the TyG index or TG/HDL-C ratio. The associations of TyG index, TG/HDL-C ratio, and their components with CRC risk were assessed using Cox proportional hazards regression models. RESULTS: During a median follow-up of 13.02 years, 593 incident CRC cases were identified. Compared with the lowest quartile of the TyG index (Q1), the risk of CRC was higher in persons in the third (Q3) and highest quartiles (Q4) of the TyG index, with corresponding multivariable-adjusted HRs (95% CI) of 1.36 (1.06, 1.76) and 1.50 (1.19, 1.91), respectively. The elevated risks of CRC incidence were observed in people in the second, third, and highest quartiles of the TG/HDL-C ratio groups, with corresponding multivariable-adjusted HRs (95% CI) of 1.33 (1.05, 1.70), 1.36 (1.07, 1.73) and 1.37 (1.07, 1.75), respectively. CONCLUSIONS: Elevated TyG index and TG/HDL-C ratio were associated with a higher risk of developing CRC among adults in Northern China.
Authors: R E Schoen; C M Tangen; L H Kuller; G L Burke; M Cushman; R P Tracy; A Dobs; P J Savage Journal: J Natl Cancer Inst Date: 1999-07-07 Impact factor: 13.506
Authors: Amanda J Cross; Leah M Ferrucci; Adam Risch; Barry I Graubard; Mary H Ward; Yikyung Park; Albert R Hollenbeck; Arthur Schatzkin; Rashmi Sinha Journal: Cancer Res Date: 2010-03-09 Impact factor: 12.701
Authors: A H Kissebah; N Vydelingum; R Murray; D J Evans; A J Hartz; R K Kalkhoff; P W Adams Journal: J Clin Endocrinol Metab Date: 1982-02 Impact factor: 5.958
Authors: Tobias Pischon; Petra H Lahmann; Heiner Boeing; Christine Friedenreich; Teresa Norat; Anne Tjønneland; Jytte Halkjaer; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Gregory Guernec; Manuela M Bergmann; Jakob Linseisen; Nikolaus Becker; Antonia Trichopoulou; Dimitrios Trichopoulos; Sabina Sieri; Domenico Palli; Rosario Tumino; Paolo Vineis; Salvatore Panico; Petra H M Peeters; H Bas Bueno-de-Mesquita; Hendriek C Boshuizen; Bethany Van Guelpen; Richard Palmqvist; Göran Berglund; Carlos Alberto Gonzalez; Miren Dorronsoro; Aurelio Barricarte; Carmen Navarro; Carmen Martinez; J Ramón Quirós; Andrew Roddam; Naomi Allen; Sheila Bingham; Kay-Tee Khaw; Pietro Ferrari; Rudolf Kaaks; Nadia Slimani; Elio Riboli Journal: J Natl Cancer Inst Date: 2006-07-05 Impact factor: 13.506
Authors: Steven C Moore; I-Min Lee; Elisabete Weiderpass; Peter T Campbell; Joshua N Sampson; Cari M Kitahara; Sarah K Keadle; Hannah Arem; Amy Berrington de Gonzalez; Patricia Hartge; Hans-Olov Adami; Cindy K Blair; Kristin B Borch; Eric Boyd; David P Check; Agnès Fournier; Neal D Freedman; Marc Gunter; Mattias Johannson; Kay-Tee Khaw; Martha S Linet; Nicola Orsini; Yikyung Park; Elio Riboli; Kim Robien; Catherine Schairer; Howard Sesso; Michael Spriggs; Roy Van Dusen; Alicja Wolk; Charles E Matthews; Alpa V Patel Journal: JAMA Intern Med Date: 2016-06-01 Impact factor: 21.873